Dr. Reddyâs Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļRDY
āļāļ·āđāļāļāļĢāļīāļĐāļąāļDr Reddy's Laboratories Ltd
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 01, 1986
āļāļĩāļāļĩāđāļMr. Deepak Sapra
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ27811
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJan 01
āļāļĩāđāļāļĒāļđāđ8-2-337, Road No.3 Banjara Hills
āđāļĄāļ·āļāļHYDERABAD
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđAustralian Stock Exchange Ltd
āļāļĢāļ°āđāļāļĻIndia
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ500034
āđāļāļĢāļĻāļąāļāļāđ914049002900
āđāļ§āđāļāđāļāļāđhttps://www.drreddys.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļRDY
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJan 01, 1986
āļāļĩāļāļĩāđāļMr. Deepak Sapra
Mr. Deepak Sapra
Chief Executive Officer - API and Services
Chief Executive Officer - API and Services
Mr. Sanjiv Soshil Mehta
Non-Executive Independent Director
Non-Executive Independent Director
Mr. Phanimitra (Phani) B
Chief Digital and Information Officer
Chief Digital and Information Officer
Mr. Mannam Venkata Narasimham
Mr. Mannam Venkata Narasimham
Chief Financial Officer
Mr. K. Randhir Singh
Compliance Officer, Company Secretary, Head - CSR
Compliance Officer, Company Secretary, Head - CSR
Mr. Kallam Satish Reddy
Executive Chairman of the Board
Executive Chairman of the Board
Richa Periwal
Investor Relations
Ms. Chan (Penny) Wan
Non-Executive Independent Director
Non-Executive Independent Director
Mr. Arun Madhavan Kumar
Non-Executive Independent Director
Non-Executive Independent Director
Mr. Sanjay Sharma
Head - Global Operations
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Deepak Sapra
Chief Executive Officer - API and Services
Chief Executive Officer - API and Services
Mr. Sanjiv Soshil Mehta
Non-Executive Independent Director
Non-Executive Independent Director
Mr. Phanimitra (Phani) B
Chief Digital and Information Officer
Chief Digital and Information Officer
Mr. Mannam Venkata Narasimham
Mr. Mannam Venkata Narasimham
Chief Financial Officer
Mr. K. Randhir Singh
Compliance Officer, Company Secretary, Head - CSR
Compliance Officer, Company Secretary, Head - CSR
Mr. Kallam Satish Reddy
Executive Chairman of the Board
Executive Chairman of the Board
National Security Emerging Markets Index ETF
Invesco S&P Emerging Markets Low Volatility ETF
Lattice Hartford Multifactor Emerging Markets ETF
DFA Dimensional Emerging Markets Value ETF
SPDR MSCI Emerging Markets StrategicFactors ETF
SP Funds S&P World (ex-US) ETF
SPDR Portfolio Emerging Markets ETF
Avantis Emerging Markets Equity ETF
DFA Dimensional Emerging Mkts High Proftblty ETF
ActivePassive International Equity ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
National Security Emerging Markets Index ETF
āļŠāļąāļāļŠāđāļ§āļ0.89%
Invesco S&P Emerging Markets Low Volatility ETF
āļŠāļąāļāļŠāđāļ§āļ0.41%
Lattice Hartford Multifactor Emerging Markets ETF
āļŠāļąāļāļŠāđāļ§āļ0.35%
DFA Dimensional Emerging Markets Value ETF
āļŠāļąāļāļŠāđāļ§āļ0.26%
SPDR MSCI Emerging Markets StrategicFactors ETF
āļŠāļąāļāļŠāđāļ§āļ0.18%
SP Funds S&P World (ex-US) ETF
āļŠāļąāļāļŠāđāļ§āļ0.17%
SPDR Portfolio Emerging Markets ETF
āļŠāļąāļāļŠāđāļ§āļ0.15%
Avantis Emerging Markets Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.14%
DFA Dimensional Emerging Mkts High Proftblty ETF
āļŠāļąāļāļŠāđāļ§āļ0.14%
ActivePassive International Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.13%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
332.70M
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
RDY.NB Final Cash Dividend of gross USD 0.476153 paid on Aug 12, 2024 going ex on Jul 30, 2024
RDY.NB Final Cash Dividend of gross USD 0.482608 paid on Aug 11, 2023 going ex on Jul 28, 2023
RDY.NB Final Cash Dividend of gross USD 0.378434 paid on Aug 12, 2022 going ex on Aug 01, 2022
RDY.NB Final Cash Dividend of gross USD 0.336485 paid on Aug 11, 2021 going ex on Jul 30, 2021
RDY.NB Final Cash Dividend of gross USD 0.333364 paid on Aug 17, 2020 going ex on Jul 10, 2020